Global Lung Cancer Therapeutics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Therapy;

Targeted, Therapy, Immunotherapy, and Chemotherapy.

By Cancer Type;

Non-small cell lung cancer (NSCLC), and Small cell lung cancer (SCLC).

By Disease Type;

Non-small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

By Type Of Molecule;

Small Molecules and Biologics.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn458774967 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Lung Cancer Therapeutics Market (USD Million), 2021 - 2031

In the year 2024, the Global Lung Cancer Therapeutics Market was valued at USD 21,282.96 million. The size of this market is expected to increase to USD 40,689.14 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 9.7%.

The global lung cancer therapeutics market has witnessed significant growth over the past decade, driven by advancements in medical research, increasing prevalence of lung cancer, and a rising awareness of early diagnosis and treatment options. Lung cancer remains one of the most common and deadly forms of cancer worldwide, necessitating the development of innovative therapeutic solutions. With the aging population and the persistent high rates of smoking and environmental pollutants, the demand for effective lung cancer treatments continues to escalate. This has prompted extensive research and development activities, leading to the introduction of novel therapies and drugs.

One of the major drivers of the lung cancer therapeutics market is the advent of targeted therapies and immunotherapies. Traditional chemotherapy, while still widely used, is being complemented and, in some cases, replaced by these newer treatments that offer better efficacy and fewer side effects. Targeted therapies, which focus on specific genetic mutations associated with lung cancer, and immunotherapies, which harness the body’s immune system to fight cancer cells, have shown promising results in improving patient outcomes. The FDA’s approval of several new drugs in these categories has further bolstered the market, offering patients more personalized and effective treatment options.

The market is also characterized by significant investments in research and development by pharmaceutical companies, aimed at discovering and commercializing new therapeutic agents. Collaborations and partnerships between biotech firms, research institutions, and pharmaceutical giants have become increasingly common, facilitating the rapid advancement of lung cancer treatments. Additionally, the growing emphasis on precision medicine and the development of companion diagnostics are enabling more accurate identification of suitable treatments for individual patients, thereby enhancing the overall efficacy of lung cancer therapeutics.

Despite the advancements, the global lung cancer therapeutics market faces several challenges. High treatment costs, stringent regulatory requirements, and the complexity of cancer biology pose significant hurdles. Moreover, disparities in access to advanced treatments between developed and developing regions remain a critical issue. Addressing these challenges requires concerted efforts from healthcare providers, policymakers, and the pharmaceutical industry to ensure that the benefits of innovative lung cancer therapies are widely accessible and affordable. As the market continues to evolve, ongoing research and technological advancements are expected to pave the way for more effective and accessible treatment options, ultimately improving the prognosis for lung cancer patients worldwide.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Therapy
    2. Market Snapshot, By Cancer Type
    3. Market Snapshot, By Disease Type
    4. Market Snapshot, By Type Of Molecule
    5. Market Snapshot, By Region
  4. Global Lung Cancer Therapeutics Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing lung cancer incidence
        2. Advancements in treatment technology
        3. Growing healthcare expenditure
        4. Rising awareness and screenings
      2. Restraints
        1. High treatment costs
        2. Stringent regulatory policies
        3. Side effects of therapies
        4. Limited availability in developing regions
      3. Opportunities
        1. Emerging markets growth
        2. Novel drug developments
        3. Personalized medicine advancements
        4. Government healthcare initiatives
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Lung Cancer Therapeutics Market, By Therapy, 2021 - 2031 (USD Million)
      1. Targeted
      2. Therapy
      3. Immunotherapy
      4. Chemotherapy
    2. Global Lung Cancer Therapeutics Market, By Cancer Type, 2021 - 2031 (USD Million)
      1. Non-small cell lung cancer (NSCLC)
      2. Small cell lung cancer (SCLC)
    3. Global Lung Cancer Therapeutics Market, By Disease Type, 2021 - 2031 (USD Million)
      1. Non-small cell lung cancer (NSCLC)
      2. Small cell lung cancer (SCLC)
    4. Global Lung Cancer Therapeutics Market, By Type Of Molecule, 2021 - 2031 (USD Million)
      1. Small molecules
      2. Biologics
    5. Global Lung Cancer Therapeutics Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. AstraZeneca
      2. Roche
      3. Bristol-Myers Squibb
      4. Merck
      5. Pfizer
      6. Novartis
      7. Eli Lilly and Company
      8. Boehringer Ingelheim
      9. Takeda Pharmaceutical Company
      10. Celgene Corporation
  7. Analyst Views
  8. Future Outlook of the Market